Invesaro

Stocks Health care YBGJ

OTC · Health care

Yubo International Biotech Ltd (YBGJ)

Yubo International Biotech Ltd brought in $12.4K of revenue over the twelve months to June 30, 2026. It posted a net loss of $933.8K. At June 30, 2026 it held $12K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Watch YBGJ in 60 seconds
Price
$0.01
0.00% on the day · September 25, 2026
52-week range $0.00 to $0.02
Market cap
$1.8M
Revenue (last 12 months)
$12.4K
Net margin
-7,559.6%

What Yubo International Biotech Ltd does

Yubo International Biotech Ltd is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker YBGJ.

Revenue and profit by year

Revenue
FY19: $0 $0 FY19FY20: $0 $0 FY20FY21: $1.2M $1.2M FY21FY22: $104.3K $104.3K FY22FY23: $604.7K $604.7K FY23FY24: $3.5K $3.5K FY24FY25: $12.4K $12.4K FY25
Net income
FY19: -$148K -$148K FY19FY20: -$134K -$134K FY20FY20: -$711.8K -$711.8K FY20FY21: -$1.5M -$1.5M FY21FY22: -$1.2M -$1.2M FY22FY23: -$1.2M -$1.2M FY23FY24: -$1.8M -$1.8M FY24FY25: -$1.1M -$1.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$12.4K-$1.2M-$1.1M-$0.01n/a
2024$3.5K-$1.8M-$1.8M-$0.02n/a
2023$604.7K-$1.2M-$1.2M-$0.10n/a
2022$104.3K-$1.2M-$1.2Mn/a-$601K
2021$1.2M-$1.5M-$1.5Mn/a-$1.6M
2020n/a-$711.8K-$711.8Kn/a$58.6K

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Where YBGJ ranks in Health care

Revenue$12.4K
#732 of 742 in Health care · Bottom 1%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Yubo International Biotech Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
  2. June 12, 2026
  3. June 12, 2026
  4. May 15, 2026
    Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
  5. March 31, 2026
    Annual report 10-K · period to December 31, 2025Revenue rose 256% to $12.4K versus the prior year; diluted EPS -$0.01 versus -$0.02.
  6. January 16, 2026
  7. November 14, 2025
    Quarterly report 10-Q · period to September 30, 2025Diluted EPS $0.00 versus -$0.01.
  8. August 13, 2025
    Quarterly report 10-Q · period to June 30, 2025Diluted EPS was $0.00.
  9. July 25, 2025
  10. July 25, 2025

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 25, 2025. Insider transactions on SEC

Who owns YBGJ

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Flydragon International Ltd13D, may seek influence with 1 related filers 48.1% 81,943,800 July 25, 2025
Boao Biotech Ltd13G, passive with 1 related filers 16.6% 19,927,660 June 3, 2025
Chinaone Technology Ltd13D, may seek influence with 1 related filers 15.1% 25,811,400 July 25, 2025

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about YBGJ

What does Yubo International Biotech Ltd do?

Yubo International Biotech Ltd is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker YBGJ.

Is Yubo International Biotech Ltd profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $933.8K on revenue of $12.4K.

How much revenue does Yubo International Biotech Ltd make?

Over the twelve months to June 30, 2026 Yubo International Biotech Ltd reported revenue of $12.4K.

When did Yubo International Biotech Ltd last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.

Similar companies

Compare YBGJ with

Compare YBGJ with any company

Follow YBGJ

Get an email when Yubo International Biotech Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow YBGJ: get an email when it files

Where the numbers come from

Financial figures are the values Yubo International Biotech Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.